Joseph Ndika, Senior Scientist, Antigen Analytics holds a PhD in Clinical Chemistry from Vrije University Medical Center, Amsterdam, Netherlands. Dr Ndika has over 14 years of experience using proteomics (mass spectrometry) and transcriptomics (next generation sequencing, microarrays) profiling of clinical samples to; study perturbation of biological pathways in rare genetic disorders, unravel allergic disease mechanisms and identify diagnostic biomarkers of adverse environmental exposures. Prior to joining Valo Therapeutics, Dr Ndika has worked on projects to develop in vitro assays to study genetic adaptation (FOM-AMOLF, Netherlands), and predict the pathogenicity of novel gene mutations associated with inborn genetic errors of metabolism (VUMC, Netherlands). In the last 6 years, his research activities have been primarily situated at the University of Helsinki, where he optimized/developed liquid chromatography mass spectrometry methods to study nanoparticle-protein interactions, investigate respiratory allergy biomarkers in patient-derived nasal brush/biopsy samples, or identify allergens from biological pesticides. He is co-author on over 27 peer-reviewed publications.
